Caruana et al. [46] demonstrated that ex vivo manipulated CAR T cells may downregulate ECM-degrading enzymes and overexpression heparanase improved CAR T cell infiltration and anti-tumour activity in vivo. The gene discussed is HPSE; the disease is neoplasm.